Table 1 Baseline characteristics.
Characteristics | No. of patients % (infusion) (n = 87) | No. of patients % (leukapheresis) (n = 92) |
|---|---|---|
Age (years), no. (%) | ||
<60 | 71 (82%) | 75 (82%) |
≥60 | 16 (18%) | 17 (18%) |
Sex, no. (%) | ||
Male | 41 (47%) | 42 (46%) |
Female | 46 (53%) | 50 (54%) |
ECOG performance status score, no. (%) | ||
0–1 | 54 (62%) | 59 (64%) |
2 | 33 (38%) | 33 (36%) |
Disease stage at study entry | ||
I or II | 13 (15%) | 14 (15%) |
III or IV | 74 (85%) | 78 (85%) |
Diagnosis by central histologic review, no. (%) | ||
DLBCL | 58 (66%) | 61 (66%) |
tFL | 6 (7%) | 7 (8%) |
FL | 13 (15%) | 13 (14%) |
PMBCL | 5 (6%) | 5 (5%) |
Others | 5 (6%) | 6 (7%) |
IHC | ||
CD20+ | 87 (100%) | 92 (100%) |
CD19+ | 78 (89%) | 83 (90%) |
CD19− | 4 (5%) | 4 (4%) |
CD19 missing data | 5 (6%) | 5 (5%) |
Double or triple protein expression: MYC plus BCL2, BCL6 or both, no. (%) | ||
Yes | 30 (34%) | 33 (36%) |
No | 38 (44%) | 40 (43%) |
Missing data | 19 (22%) | 19 (21%) |
Ki-67 (≥70%) | 54 (62%) | 57 (62%) |
Extranodal organ involvement, no. (%) | ||
Yes | 62 (71%) | 65 (71%) |
No | 25 (29%) | 27 (29%) |
No. of previous lines of antineoplastic therapy, no. (%) | ||
≤2 | 23 (27%) | 24 (26%) |
3–5 | 49 (56%) | 52 (57%) |
≥6 | 15 (17%) | 16 (17%) |
Refractory or relapse, no. (%) | ||
Refractory | 70 (80%) | 74 (80%) |
Relapse to second-line or later therapy | 17 (20%) | 18 (20%) |
Relapse after ASCT | 12 (14%) | 12 (13%) |
Relapse after previous CD19 CAR T cell therapy | 9 (10%) | 9 (10%) |
Tumour burden | ||
SPD ≥ 100 cm2 | 24 (28%) | 27 (29%) |
SPD < 100 cm2 | 63 (72%) | 65 (71%) |
Bulky/non-bulky disease | ||
Lesion diameter ≥ 10 cm | 19 (22%) | 21 (23%) |
Lesion diameter < 10 cm | 68 (78%) | 71 (77%) |
